ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
BCAL DIAGNOSTICS LTD
0.090
-0.001
-1.10%
成交量:
88.22万
成交额:
7.94万
市值:
3,312.61万
市盈率:
-4.49
高:
0.091
开:
0.091
低:
0.090
收:
0.091
52周最高:
0.155
52周最低:
0.052
股本:
3.68亿
流通股本:
2.02亿
量比:
6.47
换手率:
0.44%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.020
每股收益(LYR):
-0.020
净资产收益率:
-273.29%
总资产收益率:
-50.29%
市净率:
-40.09
市盈率(LYR):
-4.50
数据加载中...
总览
公司
新闻资讯
公告
BCAL Diagnostics澄清:未与GSS或MAP进行任何并购谈判或提案往来
美股速递
·
09/10
BCAL Diagnostics:文中所引述言论源自部分主张三方合并的基金管理人之观点
美股速递
·
09/10
BCAL诊断公司:要求罢免Michael Aicher,并提名Forrester与Melki进入GSS董事会
美股速递
·
09/03
遗传特征公司要求BCAL诊断澄清其在GSS的持股及关联方详情
美股速递
·
09/03
BCAL Diagnostics将收购Genetic Signatures股份
投资观察
·
07/07
BCAL诊断公司与Sonic Healthcare USA或就验证后的Breastestplus V2版本商谈商业许可
美股速递
·
05/28
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/BDX.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","market":"AU","secType":"STK","nameCN":"BCAL DIAGNOSTICS LTD","latestPrice":0.09,"timestamp":1791868320000,"preClose":0.091,"halted":0,"volume":882246,"delay":0,"changeRate":-0.010989010989010999,"nameEN":"BCAL DIAGNOSTICS LTD","floatShares":202437334,"shares":368067640,"eps":-0.020055,"marketStatus":"已收盘","change":-0.001,"latestTime":"10-13 16:12:00 AEDT","open":0.091,"high":0.091,"low":0.09,"amount":79403,"amplitude":0.010989,"askPrice":0.089,"askSize":11000,"bidPrice":0.06,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.020055,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.091,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":6.467567,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BDX.AU","preClose":0.09,"auctionPrice":0.09,"auctionVolume":4872,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781207709}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","floatShares":202437334,"roa":"-50.29%","roe":"-273.29%","lyrEps":-0.02,"volumeRatio":6.467567,"shares":368067640,"dividePrice":0,"high":0.091,"amplitude":0.010989,"preClose":0.091,"low":0.09,"week52Low":0.052,"pbRate":"-40.09","psRate":"14.08","week52High":0.155,"institutionHeld":0,"latestPrice":0.09,"committee":-0.047619,"eps":-0.020055,"divideRate":0,"volume":882246,"delay":0,"ttmEps":-0.020055,"open":0.091,"prevYearClose":0.105,"prevWeekClose":0.09,"prevMonthClose":0.09,"prevQuarterClose":0.09,"fiveDayClose":0.093,"twentyDayClose":0.071,"sixtyDayClose":0.071},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BDX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"BDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788393600000,"name":null,"time":"","dateTimestamp":1788357600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BDX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BDX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1126786572","title":"BCAL Diagnostics澄清:未与GSS或MAP进行任何并购谈判或提案往来","url":"https://stock-news.laohu8.com/highlight/detail?id=1126786572","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126786572?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 11:22","pubTimestamp":1789010533,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics发布声明,明确表示该公司既未主动提出、也未曾收到任何并购提案,目前亦未与GSS或MAP就合并事宜或其他形式的联合展开任何讨论。这家诊断企业强调,市场上关于其与上述实体进行潜在交易的传言缺乏事实依据。声明措辞简洁而直接,意在消除外界猜测。BCAL Diagnostics的此番表态,似乎是对近期业内传闻的正面回应——传闻曾暗示该公司可能卷入一场涉及同行业者的整合浪潮之中。这种滴水不漏的措辞,无疑是为了杜绝任何解释上的灰色地带。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180507719","title":"BCAL Diagnostics:文中所引述言论源自部分主张三方合并的基金管理人之观点","url":"https://stock-news.laohu8.com/highlight/detail?id=1180507719","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180507719?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 11:21","pubTimestamp":1789010474,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics——此前文章中提及的相关评论,实际反映的是部分基金管理人的个人见解,这些基金管理者长期以来一直积极呼吁推动三方合并事宜。\n需要明确的是,这些观点并非公司官方的正式立场。事实上,那些支持三方合并方案的基金经理们,已在多个场合公开表达过他们的倾向性看法。而文章所引用的言论,恰恰来源于这些在幕后持续推动该议程的机构投资者群体。\n在当前的资本运作讨论中,这一细节值得市场参与者给予充分关注,因为它揭示了潜在的利益相关方对未来公司架构演变的不同期待与设想。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173556031","title":"BCAL诊断公司:要求罢免Michael Aicher,并提名Forrester与Melki进入GSS董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1173556031","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173556031?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 10:42","pubTimestamp":1788403333,"startTime":"0","endTime":"0","summary":"BCAL诊断有限公司已正式提出动议,要求将Michael Aicher从Genetic Signatures Ltd董事会中罢免。与此同时,该公司还力荐Forrester及Melki两位候选人,以期他们能够顺利加入GSS董事会。这一人事调整举措,无疑为GSS公司的治理结构投下了一枚重磅炸弹。BCAL方面显然希望通过此番运作,重塑董事会的权力格局,注入新鲜血液。BCAL此举的深层动因,以及新任董事若顺利上位后将带来怎样的治理新风,均有待市场的进一步观察与解读。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","GSS.AU","BK7048","BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115211142","title":"遗传特征公司要求BCAL诊断澄清其在GSS的持股及关联方详情","url":"https://stock-news.laohu8.com/highlight/detail?id=1115211142","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115211142?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 07:39","pubTimestamp":1788392350,"startTime":"0","endTime":"0","summary":"遗传特征有限公司(Genetic Signatures Ltd, GSS.AU)已正式向BCAL诊断有限公司(BCAL Diagnostics Ltd, BDX.AU)发出请求,要求后者就其在该公司的持股情况以及关联方关系提供更为详尽的说明。\n据悉,此项请求涉及BCAL诊断在遗传特征公司中的股东身份及相关联方细节,但具体交易背景及可能引发的后续影响尚未对外披露。市场参与人士正密切关注事态发展,以评估这一动向可能对两家澳大利亚医疗诊断领域企业带来的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSS.AU","BDX.AU","BK7048","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182337442","title":"BCAL Diagnostics将收购Genetic Signatures股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1182337442","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182337442?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 16:48","pubTimestamp":1783414100,"startTime":"0","endTime":"0","summary":"7月2日——BCAL Diagnostics有限公司宣布,将收购GENETIC SIGNATURES有限公司的股份。具体而言,BCAL将以139万澳元的价格,收购GENETIC SIGNATURES公司10.2%的股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","GSS.AU","BDX.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101703832","title":"BCAL诊断公司与Sonic Healthcare USA或就验证后的Breastestplus V2版本商谈商业许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1101703832","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101703832?lang=zh_cn&edition=fundamental","pubTime":"2026-05-28 06:26","pubTimestamp":1779920771,"startTime":"0","endTime":"0","summary":"BCAL诊断公司与Sonic Healthcare USA可能在验证完成后,就第二代Breastestplus产品展开商业许可协议的谈判。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}